 Centessa Pharmaceuticals PLC ADR NASDAQ: CNTA, in partnership with its subsidiary ApcinteX Limited announced that results from its ongoing first-in-human proof-of-concept study to analyze SerpinPC in severe hemophilia A and B patients are positive. This news automatically pushed the Pharma stock up by 20 on Thursday morning. 